Bisphosphonate or RANK-L inhibitor for tumour-induced hypercalcaemia?

Neth J Med. 2012 Jun;70(5):250-1.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Bone Density Conservation Agents / therapeutic use
  • Carcinoma, Renal Cell / complications
  • Diphosphonates / therapeutic use*
  • Humans
  • Hypercalcemia / drug therapy*
  • Hypercalcemia / etiology*
  • Kidney Neoplasms / complications
  • Male
  • Middle Aged
  • RANK Ligand / antagonists & inhibitors*

Substances

  • Bone Density Conservation Agents
  • Diphosphonates
  • RANK Ligand